Assess whether pediatric studies are necessary or waivable (05f113)

Situation

Clinical and Evidence Strategy work in a biologics company planning a biosimilar pathway now turns on pediatric studies are necessary because a CRL citing manufacturing, not efficacy put complete-response-letter deficiency list in play. Clinical-development physician should say what complete-response-letter deficiency list proves.

Decision

Clinical-development physician in a biologics company planning a biosimilar pathway must choose Pediatric studies are necessary / Waivable using complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy.

Hypotheses to test

• Clinical-development physician can defend Pediatric studies are necessary from complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy in a Pharma & Life Sciences challenge.
• Clinical-development physician cannot defend Pediatric studies are necessary from complete-response-letter deficiency list; Waivable is what the extract actually supports after a CRL citing manufacturing, not efficacy.
• A CRL citing manufacturing, not efficacy never reached the population in complete-response-letter deficiency list — reopen intake, do not close pediatric studies are necessary.
• Two facts in complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy conflict for clinical-development physician; hold this Clinical and Evidence Strategy file.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on pediatric studies are necessary.
• Check whether complete-response-letter deficiency list supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in a biologics company planning a biosimilar pathway.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read complete-response-letter deficiency list against a CRL citing manufacturing, not efficacy and write the one fact that would move pediatric studies are necessary for clinical-development physician.

Recommendation

Choose Pediatric studies are necessary / Waivable on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (complete-response-letter deficiency list after a CRL citing manufacturing, not efficacy). Lead with the Pharma & Life Sciences option complete-response-letter deficiency list can support after a CRL citing manufacturing, not efficacy, then the two facts that force it, then the Monday action for clinical-development physician in a biologics company planning a biosimilar pathway.